Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
| 适应症 | Ulcerative Colitis, IBD |
|---|---|
| 分期 | 2期 |
| 申办方 | AstraZeneca |
| 状态 | 提前终止 |
| 受试者人数 | 242 人 |
| 干预（药物） | Brazikumab |
| 开始日期 | 2018年8月7日 |
| 完成日期 | 2023年10月23日 |
| 结果公布日 | 2026年6月23日 |
摘要
The present study (D5272C00001/Legacy #3151-201-008) aims to evaluate the efficacy and safety of brazikumab in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy
Clinical Remission
| Brazikumab 720 mg | 13 Participants |
|---|---|
| Brazikumab 1440 mg | 16 Participants |
| Brazikumab 2100 mg | 2 Participants |
| Vedolizumab | 0 Participants |
| Placebo | 4 Participants |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
- GI Permeability Change in Response to Aquamin® — James Varani
- A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
- Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University